Next Article in Journal
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Next Article in Special Issue
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
Previous Article in Journal
Synthesis of Imidazole-Based Medicinal Molecules Utilizing the van Leusen Imidazole Synthesis
Previous Article in Special Issue
Application of Thin-Layer Chromatography in Combination with Densitometry for the Determination of Diclofenac in Enteric Coated Tablets
Open AccessReview

[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging

1
Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
2
Molecular Biology of Systemic Radiotherapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(3), 38; https://doi.org/10.3390/ph13030038
Received: 15 January 2020 / Revised: 27 February 2020 / Accepted: 1 March 2020 / Published: 3 March 2020
(This article belongs to the Collection The Story of Successful Drugs and Recent FDA-Approved Molecules)
In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [68Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide 68Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response. View Full-Text
Keywords: [68Ga]Ga-DOTA-TOC; positron emission tomography (PET); somatostatin receptor (SSTR); neuroendocrine tumors (NETs); theranostics [68Ga]Ga-DOTA-TOC; positron emission tomography (PET); somatostatin receptor (SSTR); neuroendocrine tumors (NETs); theranostics
Show Figures

Figure 1

MDPI and ACS Style

Hennrich, U.; Benešová, M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals 2020, 13, 38.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop